IntegriChain, a leading healthcare technology company delivering a comprehensive data and analytics platform covering all core elements of pharmaceutical product access, today announced the acquisition of Medical Communication Technologies, Inc. (MCT). MCT is a top provider of government pricing and contracting software and services. IntegriChain will integrate MCT’s government pricing SaaS platform into its ICyte data platform, creating a best-in-class offering for bio/pharma manufacturers. This acquisition adds 35+ new brand and generic bio/pharma manufacturer customers to IntegriChain’s 100+ customer base and is the company’s second acquisition since entering its strategic partnership with Accel-KKR, a leading technology-focused private equity firm, in 2016.
“This acquisition offers the unique opportunity to integrate MCT’s government pricing software into ICyte’s data management foundation,” said IntegriChain Co-Founder and CEO Kevin Leininger. “Data management is one of the biggest sources of cost and complexity in government contract management, and we believe the combination of our two companies’ services represents a unique opportunity to streamline highly compliance-sensitive business processes in pharmaceutical contracting and pricing.”
“We are excited to join forces with IntegriChain and contribute to solving the access challenges that manufacturers face in today’s increasingly complex managed market environment,” said Randy Perry, President of MCT. “We are thrilled to offer our existing customers the breadth of the IntegriChain ICyte platform — across Market Access, Patient Access, and Distribution — maximizing their ability to improve the patient experience. We look forward to working with IntegriChain’s customers on their government pricing and contracting requirements.”
About IntegriChain
IntegriChain is a leading healthcare technology company for bio/pharma manufacturers, uniquely employing world-class data science to integrate all core elements of access data to deliver analytics and insights that help patients start and stay on therapy. IntegriChain’s comprehensive commercial access data and analytics platform produces insights on bio/pharma therapies throughout their market life, from the successful launch of new innovative therapies to more efficient and service-oriented channel models for mature product categories. Today IntegriChain is the trusted partner for all Top 10, 16 of the Top 20, and more than 80 other bio/pharma manufacturers, totaling more than $250 billion in annual US commerce. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm.
For more information, visit www.integrichain.com and our blog, or follow us on Twitter @IntegriChain and LinkedIn.
About MCT
Medical Communication Technologies, Inc. (MCT), is a leading provider of government pricing and contracting software and services committed to meeting the strategic challenges encountered by bio/pharma manufacturers during the key phases of product commercialization. Founded in 2000, MCT provides strategic reimbursement planning and patient services as well as commercial payer/PBM and government contracting initiatives including government pricing services; government and commercial rebate processing; commercialization and distribution planning including 3PL and specialty pharmacy selection; trade relations; and patient coupon rebate processing.
About Accel-KKR
Accel-KKR is a technology-focused investment firm with more than $4.3 billion in capital commitments. The firm focuses on software and IT-enabled businesses well-positioned for topline and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value through the significant resources available through Accel-KKR’s network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across a wide range of transaction types including private company recapitalizations, divisional carve-outs and going-private transactions. Accel-KKR is headquartered in Menlo Park with additional offices in Atlanta and London. For more information, please visit: www.accel-kkr.com.
